Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Arog Pharmaceuticals, Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit, indicating a focused prosecution effort for the company's active filings in this sector. This concentration suggests a specific research or development focus currently undergoing patent review, requiring a targeted legal strategy for this individual application.
The busiest examiner for the company is GEMBEH, SHIRLEY V, who is managing the 1 pending office action. This examiner is responsible for the company's entire pending workload as of the current data. Because there is only 1 distinct art unit involved, the prosecution process is centralized within one administrative division, which governs the examination standards for this biotechnology and pharmaceutical matter. This streamlined structure allows the company to focus its efforts on the specific technical requirements and procedural preferences of this single examiner and their respective unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GEMBEH, SHIRLEY V | 1 | 63.1% | +33.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18910067 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders | GEMBEH, SHIRLEY V | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18910067 | Crenolanib for Treating FLT3 Mutated Proliferative Disorders | GEMBEH, SHIRLEY V | 1615 | DP | Non-Final OA | — | Pending | Oct 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialArog Pharmaceuticals, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Shirley V Gembeh has the most, with 1 of Arog Pharmaceuticals, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
